SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

# Rilotumumab

**Cat. No.:** HY-P99217

**CAS No.:** 872514-65-3

**Target:** c-Met/HGFR

**Pathway:** Protein Tyrosine Kinase/RTK

**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.

## BIOLOGICAL ACTIVITY

**Description**

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2].

**In Vitro**

Rilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[2]

| | |
|---|---|
| Cell Line: | U87MG.vIII cells |
| Concentration: | 10 μg/mL |
| Incubation Time: | Overnight |
| Result: | Showed MET phosphorylation at tyrosine residue 1234 (Y1234) and Y1235 ~50% lower in U87MG.vIII cells than in untreated cells.<br>Showed an increase in total MET compared with untreated cells. |

**In Vivo**

Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|---|---|
| Animal Model: | 6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells[2] |
| Dosage: | 1.5 mg/kg |
| Administration: | Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days |
| Result: | Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001). |

## REFERENCES

[1]. Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24.

[2]. Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA